D.E. Shaw & Co
NAGE

D.E. Shaw & Co’s Niagen Bioscience NAGE Stock Holding History

D.E. Shaw & Co’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Sell
99,938
-177,443
-64% -$720K ﹤0.01% 4387
2026
Q1 		$1.22M Sell
277,381
-69,164
-20% -$373K ﹤0.01% 3286
2025
Q4 		$2.2M Sell
346,545
-199,638
-37% -$1.39M ﹤0.01% 2979
2025
Q3 		$5.1M Sell
546,183
-1,055,625
-66% -$10.7M ﹤0.01% 2193
2025
Q2 		$23.1M Buy
1,601,808
+318,018
+25% +$3.14M 0.02% 950
2025
Q1 		$8.86M Buy
1,283,790
+272,500
+27% +$1.71M 0.01% 1487
2024
Q4 		$5.36M Buy
1,011,290
+957,665
+1,786% +$5.24M ﹤0.01% 1920
2024
Q3 		$196K Buy
+53,625
New +$169K ﹤0.01% 4167
2023
Q3 		– Sell
-37,694
Closed -$59.2K – 4543
2023
Q2 		$59.2K Sell
37,694
-58,319
-61% -$87K ﹤0.01% 3867
2023
Q1 		$147K Sell
96,013
-60,433
-39% -$108K ﹤0.01% 3951
2022
Q4 		$263K Buy
156,446
+63,914
+69% +$101K ﹤0.01% 4144
2022
Q3 		$114K Buy
92,532
+25,208
+37% +$40.6K ﹤0.01% 4580
2022
Q2 		$112K Sell
67,324
-18,171
-21% -$35.5K ﹤0.01% 4706
2022
Q1 		$210K Buy
85,495
+23,453
+38% +$64.1K ﹤0.01% 4842
2021
Q4 		$232K Buy
62,042
+15,226
+33% +$82.2K ﹤0.01% 4807
2021
Q3 		$294K Sell
46,816
-41,336
-47% -$341K ﹤0.01% 4364
2021
Q2 		$869K Buy
+88,152
New +$769K ﹤0.01% 3660

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co's NAGE Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Niagen Bioscience (NAGE) stake by 64% in Q2 2026, selling an estimated $720K and leaving 99,938 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #4387.

D.E. Shaw & Co first reported a position in NAGE in Q2 2021 and has held it in 17 quarters since. The position peaked at $23.1M in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • D.E. Shaw & Co held 99,938 shares of Niagen Bioscience worth $319K as of Q2 2026.
  • D.E. Shaw & Co sold 177,443 Niagen Bioscience shares in Q2 2026, an estimated $720K.
  • Niagen Bioscience made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4387 holding.
  • D.E. Shaw & Co first reported a position in Niagen Bioscience in Q2 2021 and has held it in 17 quarters since.
  • D.E. Shaw & Co's Niagen Bioscience position peaked at $23.1M in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.